Carcinoid syndroma - diagnosis and management

Area of Science:

• Oncology
• Endocrinology

Background:

• Neuroendocrine tumors (NETs), previously called carcinoids, are rare neoplasms with an incidence of 5-8 per 10,000 people.
• NETs typically exhibit indolent behavior but can become symptomatic upon growth or metastasis.
• Approximately 30-40% of NET patients develop carcinoid syndrome, characterized by flushing, diarrhea, bronchospasm, and pellagra.

Purpose of the Study:

• To provide an overview of neuroendocrine tumors (NETs) and carcinoid syndrome.
• To describe the clinical manifestations and characteristic findings of carcinoid heart disease.
• To outline the multi-faceted treatment approaches for carcinoid syndrome in NET patients.

Main Methods:

• Literature review and synthesis of existing data on NETs and carcinoid syndrome.
• Description of clinical signs, symptoms, and diagnostic features.
• Summary of current therapeutic strategies.

Main Results:

• NETs are rare, slow-growing tumors with varying clinical presentations.
• Carcinoid syndrome presents with systemic symptoms and can lead to carcinoid heart disease, marked by endocardial deposits.
• Treatment involves tumor mass reduction, somatostatin analogues, and peptide receptor radionuclide therapy.

Conclusions:

• Neuroendocrine tumors require a comprehensive management strategy.
• Early recognition and management of carcinoid syndrome and its cardiac complications are crucial.
• Multimodal therapy offers a pathway to manage both the cancer and its associated syndrome.